Competitor
Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors
To Buy a Copy Of This Report: http://www.marketresearchreports.biz/analysis-details/competitor-analysis-therapeutic-proteins-biosimilars-biobetters-and-biosuperiors
The
new Competitive Intelligence Report Therapeutic Proteins – Biosimilars,
Biobetters & Biosuperiors of May 2013 provides a competitor analysis in the
product portfolios and development pipelines of ten major classes of
therapeutic proteins and their biosimilar and biobetter/biosuperior versions in
regulated and less regulated markets:
- Erythropoietin (EPO) & Erythropoiesis Stimulating Agents (ESA)
- G-CSF & GM-CSF
- Thrombopoietin & Thrombopoiesis Stimulating Agents
- Interferon
- Insulin
- Coagulation Factors
- Human Growth Hormone (hGH)
- FSH, hCG and LH: Therapeutic Proteins for Assisted Reproductive Technology (ART)
- Thrombolytics & Fibrinolytics
- Enzyme Replacement Therapies
Territories
covered are the major pharmaceutical markets North America, Europe and Japan,
as well as South Korea, India, China and other countries in Latin America,
Africa and Australasia.
With
more than US$ 50 bln in sales, therapeutic proteins represent a major category
of pharmaceutical products with established therapeutic value and high economic
attractiveness. As more and more of the branded products are running out of
patent protection and regulatory agencies are providing better guidance,
development of biosimilar versions as well as of improved next generation
versions are a highly attractive goal for pharmaceutical and biotechnology as
well as technology focused companies.
To
Read The Complete Report with : http://www.marketresearchreports.biz/analysis/167445
This
report includes a compilation of current active projects in research and
development of biosimilar and novel biobetter/biosuperior therapeutic proteins
as well as non-protein based competitor products and an overview of approved
products in regulated and less regulated markets. Competitor projects are
listed in a tabular format providing Information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Latest Report:
Competitor Analysis: Antibody-Drug
Conjugates (ADC): http://www.marketresearchreports.biz/analysis/166400
Product
description The present Competitive Intelligence Report about Antibody-Drug
Conjugates (ADC) / Immunoconjugates provides a competitor evaluation in the
field of tumor targeting antibodies conjugated via a linker with a drug payload
for treatment of cancer as of April 2013. Purchase of the downloadable pdf
report includes a 6-month online access to the data of the report and any
updates since the publication date. Credentials to access the database will be
sent by e-mail and allow online work with the project data to print or export
an individual report. The emerging therapeutic class of antibody-drug conjugates
(ADC) is coming of age. Two approved and marketed ADC drugs utilizing each one
of the ...
